Loading...

Chlebowski Rowan T

TitleChief
InstitutionUniversity of California Los Angeles
DepartmentMEDICAL ONCOLOGY/HEMATOLOGY
AddressTorrance CA 90509
Phone(310) 222-2217
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Kwon GP, Gamba CS, Stefanick ML, Swetter SM, Li S, Shi RZ, Clarke CA, Feldman D, Millen AE, Messina C, Shikany JM, Manson JE, Chlebowski R, Tang JY. Association of 25-hydroxyvitamin D levels and cutaneous melanoma: A nested case-control study of the Women's Health Initiative Observation Study. J Am Acad Dermatol. 2018 Jul; 79(1):145-147. PMID: 29908819.
      View in: PubMed
    2. Banack HR, Stokes A, Fox MP, Hovey KM, Cespedes-Feliciano EM, LeBlanc E, Bird C, Caan BJ, Kroenke CH, Allison MA, Going SB, Snetslaar L, Cheng TD, Chlebowski R, Stefanick ML, LaMonte MJ, Wactawski-Wende J. Stratified probabilistic bias analysis for BMI-related exposure misclassification in postmenopausal women. Epidemiology. 2018 Jun 01. PMID: 29864084.
      View in: PubMed
    3. Chlebowski R, Aragaki AK, Anderson GL, Simon MS, Manson JE, Neuhouser ML, Pan K, Stefanic ML, Rohan TE, Lane D, Qi L, Snetselaar L, Prentice RL. Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trial. JAMA Oncol. 2018 May 24; e181212. PMID: 29800122.
      View in: PubMed
    4. Shufelt C, Bairey Merz CN, Pettinger MB, Choi L, Chlebowski R, Crandall CJ, Liu S, Lane D, Prentice R, Manson JE. Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study. Menopause. 2018 May 07. PMID: 29738414.
      View in: PubMed
    5. Kabat GC, Kim MY, Lane DS, Zaslavsky O, Ho GYF, Luo J, Nicholson WK, Chlebowski R, Barrington WE, Vitolins MZ, Lin X, Liu S, Rohan TE. Serum glucose and insulin and risk of cancers of the breast, endometrium, and ovary in postmenopausal women. Eur J Cancer Prev. 2018 May; 27(3):261-268. PMID: 29438162.
      View in: PubMed
    6. Laddu DR, Wertheim BC, Garcia DO, Woods NF, LaMonte MJ, Chen B, Anton-Culver H, Zaslavsky O, Cauley JA, Chlebowski R, Manson JE, Thomson CA, Stefanick ML. 36-Item Short Form Survey (SF-36) Versus Gait Speed As Predictor of Preclinical Mobility Disability in Older Women: The Women's Health Initiative. J Am Geriatr Soc. 2018 Apr; 66(4):706-713. PMID: 29427503.
      View in: PubMed
    7. Simon MS, Beebe-Dimmer JL, Hastert TA, Manson JE, Cespedes Feliciano EM, Neuhouser ML, Ho GYF, Freudenheim JL, Strickler H, Ruterbusch J, Barac A, Chlebowski R, Caan B. Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative. Cancer. 2018 Apr 15; 124(8):1798-1807. PMID: 29338086.
      View in: PubMed
    8. Pan K, Hurria A, Chlebowski R. Breast cancer survivorship: state of the science. Breast Cancer Res Treat. 2018 Apr; 168(3):593-600. PMID: 29332134.
      View in: PubMed
    9. Jiao L, Chen L, White DL, Tinker L, Chlebowski R, Van Horn LV, Richardson P, Lane D, Sangi-Haghpeykar H, El-Serag HB. Low-fat Dietary Pattern and Pancreatic Cancer Risk in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst. 2018 Jan 01; 110(1). PMID: 28922784.
      View in: PubMed
    10. Crandall CJ, Hovey KM, Andrews CA, Chlebowski R, Stefanick ML, Lane DS, Shifren J, Chen C, Kaunitz AM, Cauley JA, Manson JE. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause. 2018 Jan; 25(1):11-20. PMID: 28816933.
      View in: PubMed
    11. Tseng VL, Chlebowski R, Yu F, Cauley JA, Li W, Thomas F, Virnig BA, Coleman AL. Association of Cataract Surgery With Mortality in Older Women: Findings from the Women's Health Initiative. JAMA Ophthalmol. 2018 Jan 01; 136(1):3-10. PMID: 29075781.
      View in: PubMed
    12. Shreibati JB, Manson JE, Margolis KL, Chlebowski R, Stefanick ML, Hlatky MA. Impact of hormone therapy on Medicare spending in the Women's Health Initiative randomized clinical trials. Am Heart J. 2018 Apr; 198:108-114. PMID: 29653631.
      View in: PubMed
    13. Sealy-Jefferson S, Cote ML, Chlebowski R, Rexrode KM, Simon MS. Post-Stroke Cancer Risk among Postmenopausal Women: The Women's Health Initiative. Womens Health Issues. 2018 Jan - Feb; 28(1):29-34. PMID: 29199053.
      View in: PubMed
    14. Kabat GC, Kim MY, Chlebowski R, Vitolins MZ, Wassertheil-Smoller S, Rohan TE. Serum lipids and risk of obesity-related cancers in postmenopausal women. Cancer Causes Control. 2018 Jan; 29(1):13-24. PMID: 29197994.
      View in: PubMed
    15. Chlebowski R, Pan K. Complexity of intermittent letrozole adjuvant therapy. Lancet Oncol. 2018 Jan; 19(1):13-15. PMID: 29158010.
      View in: PubMed
    16. Wu Y, Sarkissyan M, Clayton S, Chlebowski R, Vadgama JV. Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women. Cancers (Basel). 2017 Oct 24; 9(10). PMID: 29064397.
      View in: PubMed
    17. Nomura SJO, Dash C, Sheppard VB, Bowen D, Allison M, Barrington W, Chlebowski R, Coday M, Hou L, Howard B, LaMonte M, Manson JE, Neuhouser ML, Paskett E, Sattari M, Stefanick M, Wactawski-Wende J, Adams-Campbell LL. Sedentary time and postmenopausal breast cancer incidence. Cancer Causes Control. 2017 Dec; 28(12):1405-1416. PMID: 28975422.
      View in: PubMed
    18. Kabat GC, Kim MY, Lee JS, Ho GY, Going SB, Beebe-Dimmer J, Manson JE, Chlebowski R, Rohan TE. Metabolic Obesity Phenotypes and Risk of Breast Cancer in Postmenopausal Women. Cancer Epidemiol Biomarkers Prev. 2017 Dec; 26(12):1730-1735. PMID: 28939589.
      View in: PubMed
    19. Park NJ, Chang Y, Bender C, Conley Y, Chlebowski R, van Londen GJ, Foraker R, Wassertheil-Smoller S, Stefanick ML, Kuller LH. Cardiovascular disease and mortality after breast cancer in postmenopausal women: Results from the Women's Health Initiative. PLoS One. 2017; 12(9):e0184174. PMID: 28934233.
      View in: PubMed
    20. Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski R, Howard BV, Thomson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017 09 12; 318(10):927-938. PMID: 28898378.
      View in: PubMed
    21. Cheng TD, Song X, Beresford SAA, Ho GYF, Johnson KC, Datta M, Chlebowski R, Wactawski-Wende J, Qi L, Neuhouser ML. Serum 25-hydroxyvitamin D concentrations and lung cancer risk in never-smoking postmenopausal women. Cancer Causes Control. 2017 Oct; 28(10):1053-1063. PMID: 28900765.
      View in: PubMed
    22. Luo J, Hendryx M, Chlebowski R. Intentional weight loss and cancer risk. Oncotarget. 2017 Oct 10; 8(47):81719-81720. PMID: 29137210.
      View in: PubMed
    23. Byrne C, Ursin G, Martin CF, Peck JD, Cole EB, Zeng D, Kim E, Yaffe MD, Boyd NF, Heiss G, McTiernan A, Chlebowski R, Lane DS, Manson JE, Wactawski-Wende J, Pisano ED. Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk. J Natl Cancer Inst. 2017 09 01; 109(9). PMID: 28376149.
      View in: PubMed
    24. Kabat GC, Xue X, Kamensky V, Lane D, Bea JW, Chen C, Qi L, Stefanick ML, Chlebowski R, Wactawski-Wende J, Wassertheil-Smoller S, Rohan TE. Erratum to: Risk of breast, endometrial, colorectal, and renal cancers in postmenopausal women in association with a body shape index and other anthropometric measures. Cancer Causes Control. 2017 Sep; 28(9):1007-1009. PMID: 28752192.
      View in: PubMed
    25. Cespedes Feliciano EM, Prentice RL, Aragaki AK, Neuhouser ML, Banack HR, Kroenke CH, Ho GYF, Zaslavsky O, Strickler HD, Cheng TD, Chlebowski R, Saquib N, Nassir R, Anderson G, Caan BJ. Methodological considerations for disentangling a risk factor's influence on disease incidence versus postdiagnosis survival: The example of obesity and breast and colorectal cancer mortality in the Women's Health Initiative. Int J Cancer. 2017 12 01; 141(11):2281-2290. PMID: 28833074.
      View in: PubMed
    26. Thomson CA, Crane TE, Garcia DO, Wertheim BC, Hingle M, Snetselaar L, Datta M, Rohan T, LeBlanc E, Chlebowski R, Qi L. Association between Dietary Energy Density and Obesity-Associated Cancer: Results from the Women's Health Initiative. J Acad Nutr Diet. 2018 Apr; 118(4):617-626. PMID: 28826845.
      View in: PubMed
    27. Brasky TM, Krok-Schoen JL, Liu J, Chlebowski R, Freudenheim JL, Lavasani S, Margolis KL, Qi L, Reding KW, Shields PG, Simon MS, Wactawski-Wende J, Wang A, Womack C, Manson JE. Use of Calcium Channel Blockers and Breast Cancer Risk in the Women's Health Initiative. Cancer Epidemiol Biomarkers Prev. 2017 Aug; 26(8):1345-1348. PMID: 28765339.
      View in: PubMed
    28. Pan K, Lin EM, Chlebowski R. Emerging combination endocrine therapies for advanced breast cancer. Breast J. 2018 Mar; 24(2):214-215. PMID: 28744960.
      View in: PubMed
    29. Chlebowski R, Aragaki AK, Anderson GL, Thomson CA, Manson JE, Simon MS, Howard BV, Rohan TE, Snetselar L, Lane D, Barrington W, Vitolins MZ, Womack C, Qi L, Hou L, Thomas F, Prentice RL. Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women's Health Initiative Randomized Controlled Trial. J Clin Oncol. 2017 Sep 01; 35(25):2919-2926. PMID: 28654363.
      View in: PubMed
    30. Drieling RL, LaCroix AZ, Beresford SAA, Boudreau DM, Kooperberg C, Chlebowski R, Ko MG, Heckbert SR. Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative. J Am Geriatr Soc. 2017 Sep; 65(9):1924-1931. PMID: 28555811.
      View in: PubMed
    31. Cauley JA, Danielson ME, Jammy GR, Bauer DC, Jackson R, Wactawski-Wende J, Chlebowski R, Ensrud KE, Boudreau R. Sex Steroid Hormones and Fracture in a Multiethnic Cohort of Women: The Women's Health Initiative Study (WHI). J Clin Endocrinol Metab. 2017 May 01; 102(5):1538-1547. PMID: 28324031.
      View in: PubMed
    32. Liang X, Margolis KL, Hendryx M, Reeves K, Wassertheil-Smoller S, Weitlauf J, Danhauer SC, Chlebowski R, Caan B, Qi L, Lane D, Lavasani S, Luo J. Effect of depression before breast cancer diagnosis on mortality among postmenopausal women. Cancer. 2017 Aug 15; 123(16):3107-3115. PMID: 28387934.
      View in: PubMed
    33. Chlebowski R, Pan K, Nananda F. Response. Breast Cancer Res Treat. 2017 06; 163(3):633-634. PMID: 28353060.
      View in: PubMed
    34. Yu D, Takata Y, Smith-Warner SA, Blot W, Sawada N, White E, Freedman N, Robien K, Giovannucci E, Zhang X, Park Y, Gao YT, Chlebowski R, Langhammer A, Yang G, Severi G, Manjer J, Khaw KT, Weiderpass E, Liao LM, Caporaso N, Krokstad S, Hveem K, Sinha R, Ziegler R, Tsugane S, Xiang YB, Johansson M, Zheng W, Shu XO. Prediagnostic Calcium Intake and Lung Cancer Survival: A Pooled Analysis of 12 Cohort Studies. Cancer Epidemiol Biomarkers Prev. 2017 Jul; 26(7):1060-1070. PMID: 28264875.
      View in: PubMed
    35. Jung SY, Barrington WE, Lane DS, Chen C, Chlebowski R, Corbie-Smith G, Hou L, Zhang ZF, Paek MS, Crandall CJ. Bioavailable insulin-like growth factor-I as mediator of racial disparity in obesity-relevant breast and colorectal cancer risk among postmenopausal women. Menopause. 2017 Mar; 24(3):288-298. PMID: 27749737.
      View in: PubMed
    36. Luo J, Chlebowski R, Hendryx M, Rohan T, Wactawski-Wende J, Thomson CA, Felix AS, Chen C, Barrington W, Coday M, Stefanick M, LeBlanc E, Margolis KL. Intentional Weight Loss and Endometrial Cancer Risk. J Clin Oncol. 2017 Apr 10; 35(11):1189-1193. PMID: 28165909.
      View in: PubMed
    37. Arem H, Pfeiffer RM, Moore SC, Irwin ML, LaMonte MJ, Sarto GE, Nassir R, Luo J, Chlebowski R, Brinton LA, Matthews CE. Post-diagnosis body mass index and mortality among women diagnosed with endometrial cancer: Results from the Women's Health Initiative. PLoS One. 2017; 12(2):e0171250. PMID: 28152055.
      View in: PubMed
    38. Chlebowski R, Barrington W, Aragaki AK, Manson JE, Sarto G, O'Sullivan MJ, Wu D, Cauley JA, Qi L, Wallace RL, Prentice RL. Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial. Menopause. 2017 Feb; 24(2):133-141. PMID: 27749739.
      View in: PubMed
    39. Meggetto O, Maunsell E, Chlebowski R, Goss P, Tu D, Richardson H. Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial. J Clin Oncol. 2017 Feb 20; 35(6):629-635. PMID: 28068170.
      View in: PubMed
    40. Chlebowski R. Improving Breast Cancer Risk Assessment Versus Implementing Breast Cancer Prevention. J Clin Oncol. 2017 Mar; 35(7):702-704. PMID: 28029306.
      View in: PubMed
    41. Banegas MP, John EM, Slattery ML, Gomez SL, Yu M, LaCroix AZ, Pee D, Chlebowski R, Hines LM, Thompson CA, Gail MH. Projecting Individualized Absolute Invasive Breast Cancer Risk in US Hispanic Women. J Natl Cancer Inst. 2017 02; 109(2). PMID: 28003316.
      View in: PubMed
    42. Wang A, Aragaki AK, Tang JY, Kurian AW, Manson JE, Chlebowski R, Simon M, Desai P, Wassertheil-Smoller S, Liu S, Kritchevsky S, Wakelee HA, Stefanick ML. Reply to Comment on 'Statin use and all-cancer survival: prospective results from the Women's Health Initiative'. Br J Cancer. 2017 01; 116(3):e2. PMID: 27923034.
      View in: PubMed
    43. Haque R, Shi J, Schottinger JE, Chung J, Avila C, Amundsen B, Xu X, Barac A, Chlebowski R. Cardiovascular Disease After Aromatase Inhibitor Use. JAMA Oncol. 2016 Dec 01; 2(12):1590-1597. PMID: 27100398.
      View in: PubMed
    44. Wang A, Qin F, Hedlin H, Desai M, Chlebowski R, Gomez S, Eaton CB, Johnson KC, Qi L, Wactawski-Wende J, Womack C, Wakelee HA, Stefanick ML. Physical activity and sedentary behavior in relation to lung cancer incidence and mortality in older women: The Women's Health Initiative. Int J Cancer. 2016 Nov 15; 139(10):2178-92. PMID: 27439221.
      View in: PubMed
    45. Lohmann AE, Goodwin PJ, Chlebowski R, Pan K, Stambolic V, Dowling RJ. Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome. J Clin Oncol. 2016 Dec 10; 34(35):4249-4255. PMID: 27903146.
      View in: PubMed
    46. Chlebowski R, Reeves MM. Weight Loss Randomized Intervention Trials in Female Cancer Survivors. J Clin Oncol. 2016 Dec 10; 34(35):4238-4248. PMID: 27903147.
      View in: PubMed
    47. Goodwin PJ, Chlebowski R. Obesity and Cancer: Insights for Clinicians. J Clin Oncol. 2016 Dec 10; 34(35):4197-4202. PMID: 27903158.
      View in: PubMed
    48. Drieling RL, LaCroix AZ, Beresford SA, Boudreau DM, Kooperberg C, Chlebowski R, Gass M, Crandall CJ, Womack CR, Heckbert SR. Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative. Menopause. 2016 11; 23(11):1168-1175. PMID: 27433859.
      View in: PubMed
    49. Chlebowski R, Pan K, Col NF. Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer. Breast Cancer Res Treat. 2017 01; 161(2):185-190. PMID: 27785653.
      View in: PubMed
    50. Schonberg MA, Li VW, Eliassen AH, Davis RB, LaCroix AZ, McCarthy EP, Rosner BA, Chlebowski R, Hankinson SE, Marcantonio ER, Ngo LH. Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk. Breast Cancer Res Treat. 2016 12; 160(3):547-562. PMID: 27770283.
      View in: PubMed
    51. Garcia DO, Lander EM, Wertheim BC, Manson JE, Volpe SL, Chlebowski R, Stefanick ML, Lessin LS, Kuller LH, Thomson CA. Pet Ownership and Cancer Risk in the Women's Health Initiative. Cancer Epidemiol Biomarkers Prev. 2016 09; 25(9):1311-6. PMID: 27365150; PMCID: PMC5010503 [Available on 09/01/17].
    52. Yuan C, Qian ZR, Babic A, Morales-Oyarvide V, Rubinson DA, Kraft P, Ng K, Bao Y, Giovannucci EL, Ogino S, Stampfer MJ, Gaziano JM, Sesso HD, Buring JE, Cochrane BB, Chlebowski R, Snetselaar LG, Manson JE, Fuchs CS, Wolpin BM. Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. J Clin Oncol. 2016 Aug 20; 34(24):2899-905. PMID: 27325858; PMCID: PMC5012662 [Available on 07/20/17].
    53. Wang A, Aragaki AK, Tang JY, Kurian AW, Manson JE, Chlebowski R, Simon M, Desai P, Wassertheil-Smoller S, Liu S, Kritchevsky S, Wakelee HA, Stefanick ML. Statin use and all-cancer survival: prospective results from the Women's Health Initiative. Br J Cancer. 2016 Jun 28; 115(1):129-35. PMID: 27280630.
      View in: PubMed
    54. Chlebowski R, Budoff MJ. Changing Adjuvant Breast-Cancer Therapy with a Signal for Prevention. N Engl J Med. 2016 Jul 21; 375(3):274-5. PMID: 27263869.
      View in: PubMed
    55. Lowry SJ, Kapphahn K, Chlebowski R, Li CI. Alcohol Use and Breast Cancer Survival among Participants in the Women's Health Initiative. Cancer Epidemiol Biomarkers Prev. 2016 08; 25(8):1268-73. PMID: 27197280; PMCID: PMC4970888 [Available on 08/01/17].
    56. Tabung FK, Steck SE, Liese AD, Zhang J, Ma Y, Caan B, Chlebowski R, Freudenheim JL, Hou L, Mossavar-Rahmani Y, Shivappa N, Vitolins MZ, Wactawski-Wende J, Ockene JK, Hébert JR. Association between dietary inflammatory potential and breast cancer incidence and death: results from the Women's Health Initiative. Br J Cancer. 2016 05 24; 114(11):1277-85. PMID: 27100730.
      View in: PubMed
    57. Pan K, Chlebowski R, Simon MS, Ray RM, Livaudais-Toman J, Sullivan SD, Stefanick ML, Wallace RB, LeBoff M, Bluhm EC, Paskett ED. Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls. Breast Cancer Res Treat. 2016 Apr; 156(3):567-576. PMID: 27075917.
      View in: PubMed
    58. Weaver KE, Leach CR, Leng X, Danhauer SC, Klepin HD, Vaughan L, Naughton M, Chlebowski R, Vitolins MZ, Paskett E. Physical Functioning among Women 80 Years of Age and Older With and Without a Cancer History. J Gerontol A Biol Sci Med Sci. 2016 Mar; 71 Suppl 1:S23-30. PMID: 26858321.
      View in: PubMed
    59. Patel MI, Wang A, Kapphahn K, Desai M, Chlebowski R, Simon MS, Bird CE, Corbie-Smith G, Gomez SL, Adams-Campbell LL, Cote ML, Stefanick ML, Wakelee HA. Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women's Health Initiative. J Clin Oncol. 2016 Feb 01; 34(4):360-8. PMID: 26700122; PMCID: PMC4872034 [Available on 10/01/16].
    60. Gong Z, Aragaki AK, Chlebowski R, Manson JE, Rohan TE, Chen C, Vitolins MZ, Tinker LF, LeBlanc ES, Kuller LH, Hou L, LaMonte MJ, Luo J, Wactawski-Wende J. Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative. Int J Cancer. 2016 Apr 15; 138(8):1915-27. PMID: 26616262; PMCID: PMC4830266.
    61. Schonberg MA, Li VW, Eliassen AH, Davis RB, LaCroix AZ, McCarthy EP, Rosner BA, Chlebowski R, Rohan TE, Hankinson SE, Marcantonio ER, Ngo LH. Performance of the Breast Cancer Risk Assessment Tool Among Women Age 75 Years and Older. J Natl Cancer Inst. 2016 Mar; 108(3). PMID: 26625899.
      View in: PubMed
    62. Allman R, Dite GS, Hopper JL, Gordon O, Starlard-Davenport A, Chlebowski R, Kooperberg C. SNPs and breast cancer risk prediction for African American and Hispanic women. Breast Cancer Res Treat. 2015 Dec; 154(3):583-9. PMID: 26589314; PMCID: PMC4661211.
    63. Chlebowski R, Anderson GL, Aragaki AK, Prentice R. Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index. J Natl Cancer Inst. 2016 Feb; 108(2). PMID: 26546117.
      View in: PubMed
    64. Neuhouser ML, Chlebowski R, Anderson GL. Association Between Obesity and Postmenopausal Breast Cancer Risk-Reply. JAMA Oncol. 2015 Nov; 1(8):1171. PMID: 26562425.
      View in: PubMed
    65. Chlebowski R, Wakelee H, Pettinger M, Rohan T, Liu J, Simon M, Tindle H, Messina C, Johnson K, Schwartz A, Gass M, Wactawski-Wende J. Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial. Clin Lung Cancer. 2016 Jan; 17(1):10-7.e1. PMID: 26577506.
      View in: PubMed
    66. Kato I, Chlebowski R, Hou L, Wactawski-Wende J, Ray RM, Abrams J, Bock C, Desai P, Simon MS. Menopausal estrogen therapy and non-Hodgkin's lymphoma: A post-hoc analysis of women's health initiative randomized clinical trial. Int J Cancer. 2016 Feb 01; 138(3):604-11. PMID: 26365326.
      View in: PubMed
    67. Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, Ochs-Balcom HM, Thomson CA, Caan BJ, Tinker LF, Urrutia RP, Knudtson J, Anderson GL. Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. JAMA Oncol. 2015 Aug; 1(5):611-21. PMID: 26182172.
      View in: PubMed
    68. Gunter MJ, Wang T, Cushman M, Xue X, Wassertheil-Smoller S, Strickler HD, Rohan TE, Manson JE, McTiernan A, Kaplan RC, Scherer PE, Chlebowski R, Snetselaar L, Wang D, Ho GY. Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk. J Natl Cancer Inst. 2015 Sep; 107(9). PMID: 26185195; PMCID: PMC4651104.
    69. Chlebowski R, Aragaki AK, Anderson GL. Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative. J Natl Compr Canc Netw. 2015 Jul; 13(7):917-24. PMID: 26150583.
      View in: PubMed
    70. Schwartz AG, Ray RM, Cote ML, Abrams J, Sokol RJ, Hendrix SL, Chen C, Chlebowski R, Hubbell FA, Kooperberg C, Manson JE, O'Sullivan MJ, Rohan T, Stefanick ML, Wactawski-Wende J, Wakelee H, Simon MS. Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies. J Thorac Oncol. 2015 Jul; 10(7):1004-13. PMID: 25852020; PMCID: PMC4627490.
    71. Chlebowski R. Interpreting quality-of-life data from the SOFT and TEXT trials. Lancet Oncol. 2015 Jul; 16(7):749-51. PMID: 26092819.
      View in: PubMed
    72. Lavasani S, Chlebowski R, Prentice RL, Kato I, Wactawski-Wende J, Johnson KC, Young A, Rodabough R, Hubbell FA, Mahinbakht A, Simon MS. Estrogen and colorectal cancer incidence and mortality. Cancer. 2015 Sep 15; 121(18):3261-71. PMID: 26036212.
      View in: PubMed
    73. Chlebowski R, Rohan TE, Manson JE, Aragaki AK, Kaunitz A, Stefanick ML, Simon MS, Johnson KC, Wactawski-Wende J, O'Sullivan MJ, Adams-Campbell LL, Nassir R, Lessin LS, Prentice RL. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials. JAMA Oncol. 2015 Jun; 1(3):296-305. PMID: 26181174.
      View in: PubMed
    74. Catsburg C, Gunter MJ, Tinker L, Chlebowski R, Pollak M, Strickler HD, Cote ML, Page DL, Rohan TE. Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast. J Cancer Epidemiol. 2015; 2015:203284. PMID: 26106415; PMCID: PMC4464590.
    75. Chlebowski R, Anderson GL. Menopausal hormone therapy and breast cancer mortality: clinical implications. Ther Adv Drug Saf. 2015 Apr; 6(2):45-56. PMID: 25922653; PMCID: PMC4406918.
    76. Chlebowski R, Schottinger JE, Shi J, Chung J, Haque R. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer. 2015 Jul 01; 121(13):2147-55. PMID: 25757699; PMCID: PMC4565775.
    77. Desai P, Lehman A, Chlebowski R, Kwan ML, Arun M, Manson JE, Lavasani S, Wasswertheil-Smoller S, Sarto GE, LeBoff M, Cauley J, Cote M, Beebe-Dimmer J, Jay A, Simon MS. Statins and breast cancer stage and mortality in the Women's Health Initiative. Cancer Causes Control. 2015 Apr; 26(4):529-39. PMID: 25736184.
      View in: PubMed
    78. Newcomb PA, Passarelli MN, Phipps AI, Anderson GL, Wactawski-Wende J, Ho GY, O'Sullivan MJ, Chlebowski R. Oral bisphosphonate use and risk of postmenopausal endometrial cancer. J Clin Oncol. 2015 Apr 01; 33(10):1186-90. PMID: 25713431; PMCID: PMC4372855.
    79. Soffer D, Shi J, Chung J, Schottinger JE, Wallner LP, Chlebowski R, Lentz SE, Haque R. Metformin and breast and gynecological cancer risk among women with diabetes. BMJ Open Diabetes Res Care. 2015; 3(1):e000049. PMID: 25664181; PMCID: PMC4316195.
    80. Chlebowski R. IBIS-I tamoxifen update: maturity brings questions. Lancet Oncol. 2015 Jan; 16(1):7-9. PMID: 25497695.
      View in: PubMed
    81. Kabat GC, Xue X, Kamensky V, Lane D, Bea JW, Chen C, Qi L, Stefanick ML, Chlebowski R, Wactawski-Wende J, Wassertheil-Smoller S, Rohan TE. Risk of breast, endometrial, colorectal, and renal cancers in postmenopausal women in association with a body shape index and other anthropometric measures. Cancer Causes Control. 2015 Feb; 26(2):219-229. PMID: 25430815.
      View in: PubMed
    82. Garcia DO, Wertheim BC, Manson JE, Chlebowski R, Volpe SL, Howard BV, Stefanick ML, Thomson CA. Relationships between dog ownership and physical activity in postmenopausal women. Prev Med. 2015 Jan; 70:33-8. PMID: 25449694; PMCID: PMC4274243.
    83. Chlebowski R, Pan K. Exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 10 02; 371(14):1358. PMID: 25271612.
      View in: PubMed
    84. Ligibel JA, Alfano CM, Courneya KS, Demark-Wahnefried W, Burger RA, Chlebowski R, Fabian CJ, Gucalp A, Hershman DL, Hudson MM, Jones LW, Kakarala M, Ness KK, Merrill JK, Wollins DS, Hudis CA. American Society of Clinical Oncology position statement on obesity and cancer. J Clin Oncol. 2014 Nov 01; 32(31):3568-74. PMID: 25273035; PMCID: PMC4979237.
    85. Thomson CA, Van Horn L, Caan BJ, Aragaki AK, Chlebowski R, Manson JE, Rohan TE, Tinker LF, Kuller LH, Hou L, Lane DS, Johnson KC, Vitolins MZ, Prentice RL. Cancer incidence and mortality during the intervention and postintervention periods of the Women's Health Initiative dietary modification trial. Cancer Epidemiol Biomarkers Prev. 2014 Dec; 23(12):2924-35. PMID: 25258014; PMCID: PMC4257879.
    86. Maunsell E, Chlebowski R, Ingle JN, Richardson H, Goss PE. Reply to P. Niravath et Al. J Clin Oncol. 2014 Nov 20; 32(33):3780-1. PMID: 25154825.
      View in: PubMed
    87. Spracklen CN, Wallace RB, Sealy-Jefferson S, Robinson JG, Freudenheim JL, Wellons MF, Saftlas AF, Snetselaar LG, Manson JE, Hou L, Qi L, Chlebowski R, Ryckman KK. Birth weight and subsequent risk of cancer. Cancer Epidemiol. 2014 Oct; 38(5):538-43. PMID: 25096278; PMCID: PMC4188724.
    88. Chlebowski R, Anderson GL. Menopausal hormone therapy and cancer: changing clinical observations of target site specificity. Steroids. 2014 Nov; 90:53-9. PMID: 24910928; PMCID: PMC4192019.
    89. Roth JA, Etzioni R, Waters TM, Pettinger M, Rossouw JE, Anderson GL, Chlebowski R, Manson JE, Hlatky M, Johnson KC, Ramsey SD. Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med. 2014 May 06; 160(9):594-602. PMID: 24798522; PMCID: PMC4157355.
    90. Maunsell E, Goss PE, Chlebowski R, Ingle JN, Alés-Martínez JE, Sarto GE, Fabian CJ, Pujol P, Ruiz A, Cooke AL, Hendrix S, Thayer DW, Rowland KM, Dubé P, Spadafora S, Pruthi S, Lickley L, Ellard SL, Cheung AM, Wactawski-Wende J, Gelmon KA, Johnston D, Hiltz A, Brundage M, Pater JL, Tu D, Richardson H. Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol. 2014 May 10; 32(14):1427-36. PMID: 24711552; PMCID: PMC4879707.
    91. Zhou Y, Chlebowski R, LaMonte MJ, Bea JW, Qi L, Wallace R, Lavasani S, Walsh BW, Anderson G, Vitolins M, Sarto G, Irwin ML. Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women's Health Initiative. Gynecol Oncol. 2014 Apr; 133(1):4-10. PMID: 24680584.
      View in: PubMed
    92. Zhao S, Chlebowski R, Anderson GL, Kuller LH, Manson JE, Gass M, Patterson R, Rohan TE, Lane DS, Beresford SA, Lavasani S, Rossouw JE, Prentice RL. Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. Breast Cancer Res. 2014 Mar 26; 16(2):R30. PMID: 24670297; PMCID: PMC4053241.
    93. Adams SV, Quraishi SM, Shafer MM, Passarelli MN, Freney EP, Chlebowski R, Luo J, Meliker JR, Mu L, Neuhouser ML, Newcomb PA. Dietary cadmium exposure and risk of breast, endometrial, and ovarian cancer in the Women's Health Initiative. Environ Health Perspect. 2014 Jun; 122(6):594-600. PMID: 24633137; PMCID: PMC4050510.
    94. Chlebowski R. Current concepts in breast cancer chemoprevention. Pol Arch Med Wewn. 2014; 124(4):191-9. PMID: 24618912.
      View in: PubMed
    95. Chlebowski R, Kim J, Haque R. Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res (Phila). 2014 Apr; 7(4):378-87. PMID: 24441675.
      View in: PubMed
    96. Kwan K, Chlebowski R, McTiernan A, Rodabough RJ, La Monte MJ, Martin LW, Bell C, Lane DS, Kaplan RC, Irwin ML. Walking speed, physical activity, and breast cancer in postmenopausal women. Eur J Cancer Prev. 2014 Jan; 23(1):49-52. PMID: 23669264.
      View in: PubMed
    97. Manson JE, Chlebowski R, Aragaki AK. Hormone therapy use and outcomes in the Women's Health Initiative trials--reply. JAMA. 2014 Jan 22-29; 311(4):417-8. PMID: 24449323.
      View in: PubMed
    98. Thomson CA, McCullough ML, Wertheim BC, Chlebowski R, Martinez ME, Stefanick ML, Rohan TE, Manson JE, Tindle HA, Ockene J, Vitolins MZ, Wactawski-Wende J, Sarto GE, Lane DS, Neuhouser ML. Nutrition and physical activity cancer prevention guidelines, cancer risk, and mortality in the women's health initiative. Cancer Prev Res (Phila). 2014 Jan; 7(1):42-53. PMID: 24403289.
      View in: PubMed
    99. Pan K, Chlebowski R. Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer. 2014 Jun; 14(3):147-53. PMID: 24503025.
      View in: PubMed
    100. Prentice RL, Manson JE, Anderson GL, Lacroix AZ, Shumaker SA, Chlebowski R, Howard BV, Stefanick ML, Jackson RD, Wactawski-Wende J, Rossouw JE. Women's health initiative view of estrogen avoidance and all-cause mortality. Am J Public Health. 2013 Dec; 103(12):e2. PMID: 24134350; PMCID: PMC3828989.
    101. Cauley JA, Chlebowski R, Wactawski-Wende J, Robbins JA, Rodabough RJ, Chen Z, Johnson KC, O'Sullivan MJ, Jackson RD, Manson JE. Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women's Health Initiative. J Womens Health (Larchmt). 2013 Nov; 22(11):915-29. PMID: 24131320; PMCID: PMC3882746.
    102. Stendell-Hollis NR, Thompson PA, Thomson CA, O'Sullivan MJ, Ray RM, Chlebowski R. Investigating the association of lactation history and postmenopausal breast cancer risk in the Women's Health Initiative. Nutr Cancer. 2013; 65(7):969-81. PMID: 24127779.
      View in: PubMed
    103. Manson JE, Chlebowski R, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013 Oct 02; 310(13):1353-68. PMID: 24084921; PMCID: PMC3963523.
    104. Vogtmann E, Levitan EB, Hale L, Shikany JM, Shah NA, Endeshaw Y, Lewis CE, Manson JE, Chlebowski R. Association between sleep and breast cancer incidence among postmenopausal women in the Women's Health Initiative. Sleep. 2013 Oct 01; 36(10):1437-44. PMID: 24082303; PMCID: PMC3773193.
    105. Prentice RL, Pettinger M, Tinker LF, Huang Y, Thomson CA, Johnson KC, Beasley J, Anderson G, Shikany JM, Chlebowski R, Neuhouser ML. Regression calibration in nutritional epidemiology: example of fat density and total energy in relationship to postmenopausal breast cancer. Am J Epidemiol. 2013 Dec 01; 178(11):1663-72. PMID: 24064741; PMCID: PMC3842904.
    106. Farhat GN, Parimi N, Chlebowski R, Manson JE, Anderson G, Huang AJ, Vittinghoff E, Lee JS, Lacroix AZ, Cauley JA, Jackson R, Grady D, Lane DS, Phillips L, Simon MS, Cummings SR. Sex hormone levels and risk of breast cancer with estrogen plus progestin. J Natl Cancer Inst. 2013 Oct 02; 105(19):1496-503. PMID: 24041978; PMCID: PMC3787910.
    107. Passarelli MN, Newcomb PA, LaCroix AZ, Lane DS, Ho GY, Chlebowski R. Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative. J Bone Miner Res. 2013 Sep; 28(9):2043-8. PMID: 23519920; PMCID: PMC3799880.
    108. Desai P, Chlebowski R, Cauley JA, Manson JE, Wu C, Martin LW, Jay A, Bock C, Cote M, Petrucelli N, Rosenberg CA, Peters U, Agalliu I, Budrys N, Abdul-Hussein M, Lane D, Luo J, Park HL, Thomas F, Wactawski-Wende J, Simon MS. Prospective analysis of association between statin use and breast cancer risk in the women's health initiative. Cancer Epidemiol Biomarkers Prev. 2013 Oct; 22(10):1868-76. PMID: 23975947; PMCID: PMC3889164.
    109. Cheng TY, Lacroix AZ, Beresford SA, Goodman GE, Thornquist MD, Zheng Y, Chlebowski R, Ho GY, Neuhouser ML. Vitamin D intake and lung cancer risk in the Women's Health Initiative. Am J Clin Nutr. 2013 Oct; 98(4):1002-11. PMID: 23966428; PMCID: PMC3778856.
    110. Chlebowski R, Pettinger M, Johnson KC, Wallace R, Womack C, Mossavar-Rahmani Y, Stefanick M, Wactawski-Wende J, Carbone L, Lu B, Eaton C, Walitt B, Kooperberg CL. Calcium plus vitamin D supplementation and joint symptoms in postmenopausal women in the women's health initiative randomized trial. J Acad Nutr Diet. 2013 Oct; 113(10):1302-10. PMID: 23954097.
      View in: PubMed
    111. Chlebowski R. Adjuvant aromatase inhibitor options in overweight and obese postmenopausal women with breast cancer. Breast J. 2013 Sep-Oct; 19(5):552-4. PMID: 23941577.
      View in: PubMed
    112. Chlebowski R. Nutrition and physical activity influence on breast cancer incidence and outcome. Breast. 2013 Aug; 22 Suppl 2:S30-7. PMID: 24074789.
      View in: PubMed
    113. Chlebowski R, Nikolaenko L, Anderson G. Conduct of the Women's Health Initiative randomised trial evaluating estrogen plus progestin: implications for breast cancer findings. J Fam Plann Reprod Health Care. 2013 Jul; 39(3):226-8. PMID: 23781083.
      View in: PubMed
    114. Yasmeen S, Chlebowski R, Xing G, Morris CR, Romano PS. Severity of comorbid conditions and early-stage breast cancer therapy: linked SEER-Medicare data from 1993 to 2005. Cancer Med. 2013 Aug; 2(4):526-36. PMID: 24156025; PMCID: PMC3799287.
    115. Cossor FI, Adams-Campbell LL, Chlebowski R, Gunter MJ, Johnson K, Martell RE, McTiernan A, Simon MS, Rohan T, Wallace RB, Paulus JK. Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. Cancer Epidemiol. 2013 Oct; 37(5):742-9. PMID: 23773299; PMCID: PMC3769471.
    116. Chlebowski R, Cirillo DJ, Eaton CB, Stefanick ML, Pettinger M, Carbone LD, Johnson KC, Simon MS, Woods NF, Wactawski-Wende J. Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. Menopause. 2013 Jun; 20(6):600-8. PMID: 23511705; PMCID: PMC3855295.
    117. Salmoirago-Blotcher E, Fitchett G, Hovey KM, Schnall E, Thomson C, Andrews CA, Crawford S, O'Sullivan MJ, Post S, Chlebowski R, Ockene J. Frequency of private spiritual activity and cardiovascular risk in postmenopausal women: the Women's Health Initiative. Ann Epidemiol. 2013 May; 23(5):239-45. PMID: 23621989.
      View in: PubMed
    118. Kaklamani VG, Hoffmann TJ, Thornton TA, Hayes G, Chlebowski R, Van Horn L, Mantzoros C. Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Women's Health Initiative. Breast Cancer Res Treat. 2013 Jun; 139(2):461-8. PMID: 23624817; PMCID: PMC3773607.
    119. Chlebowski R, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC, Wactawski-Wende J, Chen C, Qi L, Yasmeen S, Newcomb PA, Prentice RL. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst. 2013 Apr 17; 105(8):526-35. PMID: 23543779; PMCID: PMC3691942.
    120. Chlebowski R. Vitamin D and breast cancer incidence and outcome. Anticancer Agents Med Chem. 2013 Jan; 13(1):98-106. PMID: 23094925.
      View in: PubMed
    121. Livaudais JC, Lacroix A, Chlebowski R, Li CI, Habel LA, Simon MS, Thompson B, Erwin DO, Hubbell FA, Coronado GD. Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative. Cancer Epidemiol Biomarkers Prev. 2013 Mar; 22(3):365-73. PMID: 23275187; PMCID: PMC3596451.
    122. Chlebowski R. Changing concepts of hormone receptor-positive advanced breast cancer therapy. Clin Breast Cancer. 2013 Jun; 13(3):159-66. PMID: 23228361.
      View in: PubMed
    123. Arem H, Chlebowski R, Stefanick ML, Anderson G, Wactawski-Wende J, Sims S, Gunter MJ, Irwin ML. Body mass index, physical activity, and survival after endometrial cancer diagnosis: results from the Women's Health Initiative. Gynecol Oncol. 2013 Feb; 128(2):181-6. PMID: 23127972.
      View in: PubMed
    124. Kuiper JG, Phipps AI, Neuhouser ML, Chlebowski R, Thomson CA, Irwin ML, Lane DS, Wactawski-Wende J, Hou L, Jackson RD, Kampman E, Newcomb PA. Recreational physical activity, body mass index, and survival in women with colorectal cancer. Cancer Causes Control. 2012 Dec; 23(12):1939-48. PMID: 23053793; PMCID: PMC3499635.
    125. Simon MS, Chlebowski R, Wactawski-Wende J, Johnson KC, Muskovitz A, Kato I, Young A, Hubbell FA, Prentice RL. Estrogen plus progestin and colorectal cancer incidence and mortality. J Clin Oncol. 2012 Nov 10; 30(32):3983-90. PMID: 23008295; PMCID: PMC3488271.
    126. Mackey RH, Fanelli TJ, Modugno F, Cauley JA, McTigue KM, Brooks MM, Chlebowski R, Manson JE, Klug TL, Kip KE, Curb JD, Kuller LH. Hormone therapy, estrogen metabolism, and risk of breast cancer in the Women's Health Initiative Hormone Therapy Trial. Cancer Epidemiol Biomarkers Prev. 2012 Nov; 21(11):2022-32. PMID: 22933427; PMCID: PMC3493689.
    127. Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski R. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat. 2012 Oct; 135(3):639-46. PMID: 22847511.
      View in: PubMed
    128. Lin JH, Gunter MJ, Manson JE, Rexrode KM, Cook NR, Kraft P, Cochrane BB, Chlebowski R, Ho GY, Zhang SM. The aromatase gene (CYP19A1) variants and circulating hepatocyte growth factor in postmenopausal women. PLoS One. 2012; 7(7):e42079. PMID: 22848710; PMCID: PMC3405042.
    129. Bukowski R, Chlebowski R, Thune I, Furberg AS, Hankins GD, Malone FD, D'Alton ME. Birth weight, breast cancer and the potential mediating hormonal environment. PLoS One. 2012; 7(7):e40199. PMID: 22815728; PMCID: PMC3398929.
    130. Chlebowski R, Col N. Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors. Breast J. 2012 Jul-Aug; 18(4):299-302. PMID: 22681627.
      View in: PubMed
    131. Chlebowski R, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, Ipp E, Kaklamani VG, Vitolins M, Wallace R, Gunter M, Phillips LS, Strickler H, Margolis K, Euhus DM. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol. 2012 Aug 10; 30(23):2844-52. PMID: 22689798; PMCID: PMC3826090.
    132. Luo J, Chlebowski R, Liu S, McGlynn KA, Parekh N, White DL, Margolis KL. Diabetes mellitus as a risk factor for gastrointestinal cancers among postmenopausal women. Cancer Causes Control. 2013 Mar; 24(3):577-85. PMID: 22622863.
      View in: PubMed
    133. Luo J, Chlebowski R, Wactawski-Wende J, Schlecht NF, Tinker L, Margolis KL. Diabetes and lung cancer among postmenopausal women. Diabetes Care. 2012 Jul; 35(7):1485-91. PMID: 22619084; PMCID: PMC3379607.
    134. Hvidtfeldt UA, Gunter MJ, Lange T, Chlebowski R, Lane D, Farhat GN, Freiberg MS, Keiding N, Lee JS, Prentice R, Tjønneland A, Vitolins MZ, Wassertheil-Smoller S, Strickler HD, Rod NH. Quantifying mediating effects of endogenous estrogen and insulin in the relation between obesity, alcohol consumption, and breast cancer. Cancer Epidemiol Biomarkers Prev. 2012 Jul; 21(7):1203-12. PMID: 22564867; PMCID: PMC3858186.
    135. Ho GY, Wang T, Gunter MJ, Strickler HD, Cushman M, Kaplan RC, Wassertheil-Smoller S, Xue X, Rajpathak SN, Chlebowski R, Vitolins MZ, Scherer PE, Rohan TE. Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res. 2012 Jun 15; 72(12):3029-37. PMID: 22511581; PMCID: PMC3790260.
    136. Chlebowski R, Anderson GL. Changing concepts: Menopausal hormone therapy and breast cancer. J Natl Cancer Inst. 2012 Apr 04; 104(7):517-27. PMID: 22427684; PMCID: PMC3317878.
    137. Huang Y, Ballinger DG, Dai JY, Peters U, Hinds DA, Cox DR, Beilharz E, Chlebowski R, Rossouw JE, McTiernan A, Rohan T, Prentice RL. Genetic variants in the MRPS30 region and postmenopausal breast cancer risk. Genome Med. 2012 Mar 12; 4(3):19. PMID: 22410340; PMCID: PMC3446269.
    138. Anderson GL, Chlebowski R, Aragaki AK, Kuller LH, Manson JE, Gass M, Bluhm E, Connelly S, Hubbell FA, Lane D, Martin L, Ockene J, Rohan T, Schenken R, Wactawski-Wende J. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012 May; 13(5):476-86. PMID: 22401913; PMCID: PMC3412626.
    139. Kroenke CH, Michael Y, Tindle H, Gage E, Chlebowski R, Garcia L, Messina C, Manson JE, Caan BJ. Social networks, social support and burden in relationships, and mortality after breast cancer diagnosis. Breast Cancer Res Treat. 2012 May; 133(1):375-85. PMID: 22331479; PMCID: PMC4856003.
    140. Chlebowski R, Col N. Bisphosphonates and breast cancer prevention. Anticancer Agents Med Chem. 2012 Feb; 12(2):144-50. PMID: 21864227.
      View in: PubMed
    141. Bertone-Johnson ER, McTiernan A, Thomson CA, Wactawski-Wende J, Aragaki AK, Rohan TE, Vitolins MZ, Tamimi RM, Johnson KC, Lane D, Rexrode KM, Peck JD, Chlebowski R, Sarto G, Manson JE. Vitamin D and calcium supplementation and one-year change in mammographic density in the women's health initiative calcium and vitamin D trial. Cancer Epidemiol Biomarkers Prev. 2012 Mar; 21(3):462-73. PMID: 22253296; PMCID: PMC3297717.
    142. Chlebowski R, Pettinger M, Kooperberg C. Caution in reinterpreting the Women's Health Initiative (WHI) Calcium and Vitamin D Trial breast cancer results. Am J Clin Nutr. 2012 Jan; 95(1):258-9; author reply 259. PMID: 22189262.
      View in: PubMed
    143. Chlebowski R. Obesity and breast cancer outcome: adding to the evidence. J Clin Oncol. 2012 Jan 10; 30(2):126-8. PMID: 22162565.
      View in: PubMed
    144. Wolpin BM, Ng K, Bao Y, Kraft P, Stampfer MJ, Michaud DS, Ma J, Buring JE, Sesso HD, Lee IM, Rifai N, Cochrane BB, Wactawski-Wende J, Chlebowski R, Willett WC, Manson JE, Giovannucci EL, Fuchs CS. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2012 Jan; 21(1):82-91. PMID: 22086883; PMCID: PMC3253914.
    145. Crandall CJ, Aragaki AK, Cauley JA, McTiernan A, Manson JE, Anderson G, Chlebowski R. Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials. Breast Cancer Res Treat. 2012 Feb; 132(1):275-85. PMID: 22042371; PMCID: PMC3697872.
    146. Crandall CJ, Aragaki AK, Cauley JA, McTiernan A, Manson JE, Anderson GL, Wactawski-Wende J, Chlebowski R. Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. Breast Cancer Res Treat. 2012 Feb; 131(3):969-79. PMID: 21979747; PMCID: PMC3685488.
    147. Chlebowski R. The obesity and breast cancer connection: advancing the agenda. Oncology (Williston Park). 2011 Oct; 25(11):1007, 1011-2. PMID: 22106551.
      View in: PubMed
    148. Lee P, Fu YP, Figueroa JD, Prokunina-Olsson L, Gonzalez-Bosquet J, Kraft P, Wang Z, Jacobs KB, Yeager M, Horner MJ, Hankinson SE, Hutchinson A, Chatterjee N, Garcia-Closas M, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Thun MJ, Diver R, Prentice R, Jackson R, Kooperberg C, Chlebowski R, Lissowska J, Peplonska B, Brinton LA, Tucker M, Fraumeni JF, Hoover RN, Thomas G, Hunter DJ, Chanock SJ. Fine mapping of 14q24.1 breast cancer susceptibility locus. Hum Genet. 2012 Mar; 131(3):479-90. PMID: 21959381.
      View in: PubMed
    149. Tang JY, Spaunhurst KM, Chlebowski R, Wactawski-Wende J, Keiser E, Thomas F, Anderson ML, Zeitouni NC, Larson JC, Stefanick ML. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. J Natl Cancer Inst. 2011 Oct 05; 103(19):1469-75. PMID: 21878677; PMCID: PMC3186783.
    150. Chlebowski R. Vitamin D and breast cancer: interpreting current evidence. Breast Cancer Res. 2011 Aug 16; 13(4):217. PMID: 21884640; PMCID: PMC3236325.
    151. Tippin BL, Levine AJ, Materi AM, Song WL, Keku TO, Goodman JE, Sansbury LB, Das S, Dai A, Kwong AM, Lin AM, Lin JM, Park JM, Patterson RE, Chlebowski R, Garavito RM, Inoue T, Cho W, Lawson JA, Kapoor S, Kolonel LN, Le Marchand L, Haile RW, Sandler RS, Lin HJ. Hematopoietic prostaglandin D synthase (HPGDS): a high stability, Val187Ile isoenzyme common among African Americans and its relationship to risk for colorectal cancer. Prostaglandins Other Lipid Mediat. 2012 Jan; 97(1-2):22-8. PMID: 21821144; PMCID: PMC3226866.
    152. Brunner RL, Wactawski-Wende J, Caan BJ, Cochrane BB, Chlebowski R, Gass ML, Jacobs ET, LaCroix AZ, Lane D, Larson J, Margolis KL, Millen AE, Sarto GE, Vitolins MZ, Wallace RB. The effect of calcium plus vitamin D on risk for invasive cancer: results of the Women's Health Initiative (WHI) calcium plus vitamin D randomized clinical trial. Nutr Cancer. 2011; 63(6):827-41. PMID: 21774589; PMCID: PMC3403703.
    153. Kabat GC, Kim MY, Woods NF, Habel LA, Messina CR, Wactawski-Wende J, Stefanick ML, Chlebowski R, Wassertheil-Smoller S, Rohan TE. Reproductive and menstrual factors and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. Cancer Causes Control. 2011 Oct; 22(10):1415-24. PMID: 21750889.
      View in: PubMed
    154. Shikany JM, Redden DT, Neuhouser ML, Chlebowski R, Rohan TE, Simon MS, Liu S, Lane DS, Tinker L. Dietary glycemic load, glycemic index, and carbohydrate and risk of breast cancer in the Women's Health Initiative. Nutr Cancer. 2011; 63(6):899-907. PMID: 21714685; PMCID: PMC3791879.
    155. Huang Y, Ballinger DG, Dai JY, Peters U, Hinds DA, Cox DR, Beilharz E, Chlebowski R, Rossouw JE, McTiernan A, Rohan T, Prentice RL. Genetic variants in the MRPS30 region and postmenopausal breast cancer risk. Genome Med. 2011 Jun 24; 3(6):42. PMID: 21702935; PMCID: PMC3218816.
    156. Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski R, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011 Jun 23; 364(25):2381-91. PMID: 21639806.
      View in: PubMed
    157. Lin JH, Manson JE, Kraft P, Cochrane BB, Gunter MJ, Chlebowski R, Zhang SM. Estrogen and progesterone-related gene variants and colorectal cancer risk in women. BMC Med Genet. 2011 May 31; 12:78. PMID: 21627810; PMCID: PMC3125237.
    158. Simon MS, Thomson CA, Pettijohn E, Kato I, Rodabough RJ, Lane D, Hubbell FA, O'Sullivan MJ, Adams-Campbell L, Mouton CP, Abrams J, Chlebowski R. Racial differences in colorectal cancer incidence and mortality in the Women's Health Initiative. Cancer Epidemiol Biomarkers Prev. 2011 Jul; 20(7):1368-78. PMID: 21602308.
      View in: PubMed
    159. Curtis JR, Larson JC, Delzell E, Brookhart MA, Cadarette SM, Chlebowski R, Judd S, Safford M, Solomon DH, Lacroix AZ. Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials. Med Care. 2011 May; 49(5):427-35. PMID: 21422960; PMCID: PMC4217207.
    160. Bodelon C, Anderson GL, Rossing MA, Chlebowski R, Ochs-Balcom HM, Vaughan TL. Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women. Cancer Prev Res (Phila). 2011 Jun; 4(6):840-50. PMID: 21505180; PMCID: PMC3107894.
    161. LaCroix AZ, Chlebowski R, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011 Apr 06; 305(13):1305-14. PMID: 21467283; PMCID: PMC3656722.
    162. Irwin ML, McTiernan A, Manson JE, Thomson CA, Sternfeld B, Stefanick ML, Wactawski-Wende J, Craft L, Lane D, Martin LW, Chlebowski R. Physical activity and survival in postmenopausal women with breast cancer: results from the women's health initiative. Cancer Prev Res (Phila). 2011 Apr; 4(4):522-9. PMID: 21464032; PMCID: PMC3123895.
    163. Phipps AI, Chlebowski R, Prentice R, McTiernan A, Stefanick ML, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Vitolins M, Kabat GC, Rohan TE, Li CI. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev. 2011 Mar; 20(3):454-63. PMID: 21364029; PMCID: PMC3064558.
    164. Phipps AI, Chlebowski R, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, Kabat GC, Rohan TE, Li CI. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011 Mar 16; 103(6):470-7. PMID: 21346227; PMCID: PMC3057984.
    165. Farhat GN, Cummings SR, Chlebowski R, Parimi N, Cauley JA, Rohan TE, Huang AJ, Vitolins M, Hubbell FA, Manson JE, Cochrane BB, Lane DS, Lee JS. Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst. 2011 Apr 06; 103(7):562-70. PMID: 21330633; PMCID: PMC3071353.
    166. Michael YL, Carlson NE, Bowen DJ, Ritenbaugh C, Chlebowski R, Weihs KL, Ockene JK. Re: "Invited commentary: personality as a causal factor in cancer risk and mortality--time to retire a hypothesis?". Am J Epidemiol. 2011 Mar 15; 173(6):716; author reply 716-7. PMID: 21307351.
      View in: PubMed
    167. Chlebowski R, Anderson GL. The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment. J Natl Cancer Inst. 2011 Feb 16; 103(4):284-5. PMID: 21278357.
      View in: PubMed
    168. Yasmeen S, Xing G, Morris C, Chlebowski R, Romano PS. Comorbidities and mammography use interact to explain racial/ethnic disparities in breast cancer stage at diagnosis. Cancer. 2011 Jul 15; 117(14):3252-61. PMID: 21246529.
      View in: PubMed
    169. Chlebowski R. Emerging role for bisphosphonates in cancer management. Breast Dis. 2011; 33(2):55-7. PMID: 22142659.
      View in: PubMed
    170. Chlebowski R, Col N. Bisphosphonates and breast cancer incidence and recurrence. Breast Dis. 2011; 33(2):93-101. PMID: 22142660.
      View in: PubMed
    171. Bós AM, Howard BV, Beresford SA, Urban N, Tinker LF, Waters H, Bós AJ, Chlebowski R, Ennis JM. Cost-effectiveness analysis of a low-fat diet in the prevention of breast and ovarian cancer. J Am Diet Assoc. 2011 Jan; 111(1):56-66. PMID: 21185966.
      View in: PubMed
    172. Kerwin DR, Gaussoin SA, Chlebowski R, Kuller LH, Vitolins M, Coker LH, Kotchen JM, Nicklas BJ, Wassertheil-Smoller S, Hoffmann RG, Espeland MA. Interaction between body mass index and central adiposity and risk of incident cognitive impairment and dementia: results from the Women's Health Initiative Memory Study. J Am Geriatr Soc. 2011 Jan; 59(1):107-12. PMID: 21226681.
      View in: PubMed
    173. Chlebowski R, Johnson KC, Lane D, Pettinger M, Kooperberg CL, Wactawski-Wende J, Rohan T, O'Sullivan MJ, Yasmeen S, Hiatt RA, Shikany JM, Vitolins M, Khandekar J, Hubbell FA. 25-hydroxyvitamin D concentration, vitamin D intake and joint symptoms in postmenopausal women. Maturitas. 2011 Jan; 68(1):73-8. PMID: 21093181; PMCID: PMC3860096.
    174. Bertone-Johnson ER, Chlebowski R, Manson JE, Wactawski-Wende J, Aragaki AK, Tamimi RM, Rexrode KM, Thomson CA, Rohan TE, Peck JD, Pisano ED, Martin CF, Sarto G, McTiernan A. Dietary vitamin D and calcium intake and mammographic density in postmenopausal women. Menopause. 2010 Nov-Dec; 17(6):1152-60. PMID: 20613676; PMCID: PMC2953586.
    175. Chlebowski R, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010 Oct 20; 304(15):1684-92. PMID: 20959578.
      View in: PubMed
    176. Chlebowski R, Menon R, Chaisanguanthum RM, Jackson DM. Prospective evaluation of two recruitment strategies for a randomized controlled cancer prevention trial. Clin Trials. 2010 Dec; 7(6):744-8. PMID: 20833684.
      View in: PubMed
    177. Kabat GC, Kim M, Wactawski-Wende J, Lane D, Adams-Campbell LL, Gaudet M, Stefanick ML, Vitolins M, Chlebowski R, Wassertheil-Smoller S, Rohan TE. Recreational physical activity, anthropometric factors, and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. Cancer Causes Control. 2010 Dec; 21(12):2173-81. PMID: 20814736.
      View in: PubMed
    178. Li CI, Chlebowski R, Freiberg M, Johnson KC, Kuller L, Lane D, Lessin L, O'Sullivan MJ, Wactawski-Wende J, Yasmeen S, Prentice R. Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study. J Natl Cancer Inst. 2010 Sep 22; 102(18):1422-31. PMID: 20733117; PMCID: PMC2943525.
    179. Chlebowski R, Anderson GL, Manson JE, Schwartz AG, Wakelee H, Gass M, Rodabough RJ, Johnson KC, Wactawski-Wende J, Kotchen JM, Ockene JK, O'Sullivan MJ, Hubbell FA, Chien JW, Chen C, Stefanick ML. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst. 2010 Sep 22; 102(18):1413-21. PMID: 20709992; PMCID: PMC2943522.
    180. Kabat GC, Kim M, Shikany JM, Rodgers AK, Wactawski-Wende J, Lane D, Powell L, Stefanick ML, Freiberg MS, Kazlauskaite R, Chlebowski R, Wassertheil-Smoller S, Rohan TE. Alcohol consumption and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2010 Aug; 19(8):2066-72. PMID: 20647412.
      View in: PubMed
    181. Chlebowski R, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, Lane DS, Manson JE, Snetselaar L, Yasmeen S, O'Sullivan MJ, Safford M, Hendrix SL, Wallace RB. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010 Aug 01; 28(22):3582-90. PMID: 20567009; PMCID: PMC2917313.
    182. Chlebowski R, Anderson G, Manson JE, Pettinger M, Yasmeen S, Lane D, Langer RD, Hubbell FA, McTiernan A, Hendrix S, Schenken R, Stefanick ML. Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol. 2010 Jun 01; 28(16):2690-7. PMID: 20439627; PMCID: PMC2881849.
    183. Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson HS, Diver WR, Thun MJ, Cox DG, Hankinson SE, Kraft P, Rosner B, Berg CD, Brinton LA, Lissowska J, Sherman ME, Chlebowski R, Kooperberg C, Jackson RD, Buckman DW, Hui P, Pfeiffer R, Jacobs KB, Thomas GD, Hoover RN, Gail MH, Chanock SJ, Hunter DJ. Performance of common genetic variants in breast-cancer risk models. N Engl J Med. 2010 Mar 18; 362(11):986-93. PMID: 20237344.
      View in: PubMed
    184. Chlebowski R. Lifestyle and breast cancer risk: the way forward? J Clin Oncol. 2010 Mar 20; 28(9):1445-7. PMID: 20159802.
      View in: PubMed
    185. Li CI, Mathes RW, Bluhm EC, Caan B, Cavanagh MF, Chlebowski R, Michael Y, O'Sullivan MJ, Stefanick ML, Prentice R. Migraine history and breast cancer risk among postmenopausal women. J Clin Oncol. 2010 Feb 20; 28(6):1005-10. PMID: 20100960; PMCID: PMC2834426.
    186. Chlebowski R, Stefanick ML. Hormone therapy suspension and mammography in Women's Health Initiative clinical trials. Ann Intern Med. 2010 Jan 19; 152(2):133. PMID: 20083839.
      View in: PubMed
    187. Prentice RL, Huang Y, Hinds DA, Peters U, Cox DR, Beilharz E, Chlebowski R, Rossouw JE, Caan B, Ballinger DG. Variation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2010 Jan; 19(1):74-9. PMID: 20056625; PMCID: PMC2806599.
    188. Chlebowski R. Re: International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2010 Jan 20; 102(2):137. PMID: 20019336.
      View in: PubMed
    189. Chlebowski R, Tagawa T. Early breast and prostate cancer and clinical outcomes (fracture). Oncology (Williston Park). 2009 Dec; 23(14 Suppl 5):16-20. PMID: 20128324.
      View in: PubMed
    190. Chlebowski R. Menopausal hormone therapy, hormone receptor status, and lung cancer in women. Semin Oncol. 2009 Dec; 36(6):566-71. PMID: 19995648.
      View in: PubMed
    191. Kabat GC, Kim M, Caan BJ, Chlebowski R, Gunter MJ, Ho GY, Rodriguez BL, Shikany JM, Strickler HD, Vitolins MZ, Rohan TE. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer. 2009 Dec 01; 125(11):2704-10. PMID: 19588485.
      View in: PubMed
    192. McTiernan A, Chlebowski R, Martin C, Peck JD, Aragaki A, Pisano ED, Wang CY, Johnson KC, Manson JE, Wallace RB, Vitolins MZ, Heiss G. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. J Clin Oncol. 2009 Dec 20; 27(36):6135-43. PMID: 19901118; PMCID: PMC2793034.
    193. Kwan KW, Chlebowski R. Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer. Clin Breast Cancer. 2009 Nov; 9(4):219-24. PMID: 19933076.
      View in: PubMed
    194. Prentice RL, Huang Y, Hinds DA, Peters U, Pettinger M, Cox DR, Beilharz E, Chlebowski R, Rossouw JE, Caan B, Ballinger DG. Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2009 Nov; 18(11):3079-85. PMID: 19861516; PMCID: PMC2783392.
    195. Crandall CJ, Aragaki AK, Chlebowski R, McTiernan A, Anderson G, Hendrix SL, Cochrane BB, Kuller LH, Cauley JA. New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk. Arch Intern Med. 2009 Oct 12; 169(18):1684-91. PMID: 19822825; PMCID: PMC3670683.
    196. Chlebowski R, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, Rodabough RJ, Chien JW, Wactawski-Wende J, Gass M, Kotchen JM, Johnson KC, O'Sullivan MJ, Ockene JK, Chen C, Hubbell FA. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet. 2009 Oct 10; 374(9697):1243-51. PMID: 19767090; PMCID: PMC2995490.
    197. Chlebowski R. Aromatase inhibitor-associated arthralgias. J Clin Oncol. 2009 Oct 20; 27(30):4932-4. PMID: 19752332.
      View in: PubMed
    198. Caan BJ, Aragaki A, Thomson CA, Stefanick ML, Chlebowski R, Hubbell FA, Tinker L, Vitolins M, Rajkovic A, Bueche M, Ockene J. Vasomotor symptoms, adoption of a low-fat dietary pattern, and risk of invasive breast cancer: a secondary analysis of the Women's Health Initiative randomized controlled dietary modification trial. J Clin Oncol. 2009 Sep 20; 27(27):4500-7. PMID: 19687338; PMCID: PMC2754902.
    199. Chlebowski R, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S, Cutuli B, Linforth R, Maass N, Noguchi S, Robidoux A, Verma S, Hadji P. Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast. 2009 Aug; 18 Suppl 2:S1-11. PMID: 19712865.
      View in: PubMed
    200. Chlebowski R. Caution regarding 25-hydroxyvitamin D monitoring in women with breast cancer. J Clin Oncol. 2009 Aug 20; 27(24):e72-3; author reply e74. PMID: 19620473.
      View in: PubMed
    201. Kabat GC, Kim M, Chlebowski R, Khandekar J, Ko MG, McTiernan A, Neuhouser ML, Parker DR, Shikany JM, Stefanick ML, Thomson CA, Rohan TE. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2009 Jul; 18(7):2046-53. PMID: 19567502.
      View in: PubMed
    202. Kabat GC, Kim M, Adams-Campbell LL, Caan BJ, Chlebowski R, Neuhouser ML, Shikany JM, Rohan TE. Longitudinal study of serum carotenoid, retinol, and tocopherol concentrations in relation to breast cancer risk among postmenopausal women. Am J Clin Nutr. 2009 Jul; 90(1):162-9. PMID: 19474140; PMCID: PMC3987813.
    203. Visvanathan K, Chlebowski R, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009 Jul 01; 27(19):3235-58. PMID: 19470930; PMCID: PMC2716943.
    204. Prentice RL, Pettinger M, Beresford SA, Wactawski-Wende J, Hubbell FA, Stefanick ML, Chlebowski R. Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. Cancer Epidemiol Biomarkers Prev. 2009 May; 18(5):1531-7. PMID: 19423530; PMCID: PMC2689377.
    205. Katayama H, Paczesny S, Prentice R, Aragaki A, Faca VM, Pitteri SJ, Zhang Q, Wang H, Silva M, Kennedy J, Rossouw J, Jackson R, Hsia J, Chlebowski R, Manson J, Hanash S. Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med. 2009 Apr 29; 1(4):47. PMID: 19402886; PMCID: PMC2684668.
    206. Hoy MK, Winters BL, Chlebowski R, Papoutsakis C, Shapiro A, Lubin MP, Thomson CA, Grosvenor MB, Copeland T, Falk E, Day K, Blackburn GL. Implementing a low-fat eating plan in the Women's Intervention Nutrition Study. J Am Diet Assoc. 2009 Apr; 109(4):688-96. PMID: 19328264.
      View in: PubMed
    207. Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, Hankinson SE, Hutchinson A, Wang Z, Yu K, Chatterjee N, Garcia-Closas M, Gonzalez-Bosquet J, Prokunina-Olsson L, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Diver R, Prentice R, Jackson R, Kooperberg C, Chlebowski R, Lissowska J, Peplonska B, Brinton LA, Sigurdson A, Doody M, Bhatti P, Alexander BH, Buring J, Lee IM, Vatten LJ, Hveem K, Kumle M, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF, Hoover RN, Chanock SJ, Hunter DJ. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet. 2009 May; 41(5):579-84. PMID: 19330030; PMCID: PMC2928646.
    208. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M, Kim D. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat. 2009 Nov; 118(1):81-7. PMID: 19308727.
      View in: PubMed
    209. Michael YL, Carlson NE, Chlebowski R, Aickin M, Weihs KL, Ockene JK, Bowen DJ, Ritenbaugh C. Influence of stressors on breast cancer incidence in the Women's Health Initiative. Health Psychol. 2009 Mar; 28(2):137-46. PMID: 19290705; PMCID: PMC2657917.
    210. Chlebowski R, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009 Feb 05; 360(6):573-87. PMID: 19196674; PMCID: PMC3963492.
    211. Chlebowski R. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer. Breast Cancer Res Treat. 2008 Dec; 112 Suppl 1:25-34. PMID: 19101792.
      View in: PubMed
    212. Zon RT, Goss E, Vogel VG, Chlebowski R, Jatoi I, Robson ME, Wollins DS, Garber JE, Brown P, Kramer BS. American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol. 2009 Feb 20; 27(6):986-93. PMID: 19075281; PMCID: PMC2668639.
    213. Chlebowski R, Prentice R. Tibolone in older postmenopausal women. N Engl J Med. 2008 Nov 13; 359(20):2172-3; author reply 2173. PMID: 19005202.
      View in: PubMed
    214. Chlebowski R, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O'Sullivan MJ, Yasmeen S, Hiatt RA, Shikany JM, Vitolins M, Khandekar J, Hubbell FA. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008 Nov 19; 100(22):1581-91. PMID: 19001601; PMCID: PMC2673920.
    215. Rohan TE, Negassa A, Chlebowski R, Ceria-Ulep CD, Cochrane BB, Lane DS, Ginsberg M, Wassertheil-Smoller S, Page DL. A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. Breast Cancer Res Treat. 2009 Jul; 116(2):339-50. PMID: 18853250; PMCID: PMC3893102.
    216. Ritenbaugh C, Stanford JL, Wu L, Shikany JM, Schoen RE, Stefanick ML, Taylor V, Garland C, Frank G, Lane D, Mason E, McNeeley SG, Ascensao J, Chlebowski R. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2008 Oct; 17(10):2609-18. PMID: 18829444; PMCID: PMC2937217.
    217. Chlebowski R, Prentice RL. Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution. J Natl Cancer Inst. 2008 Oct 01; 100(19):1341-3. PMID: 18812547.
      View in: PubMed
    218. Chlebowski R, Col N. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst. 2008 Sep 17; 100(18):1331-2; author reply 132-3. PMID: 18780870.
      View in: PubMed
    219. Chlebowski R. Toward optimal health: advances in breast cancer detection and management. Interview by Jodi R. Godfrey. J Womens Health (Larchmt). 2008 Sep; 17(7):1067-70. PMID: 18774890.
      View in: PubMed
    220. Chen Z, Arendell L, Aickin M, Cauley J, Lewis CE, Chlebowski R. Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative. Cancer. 2008 Sep 01; 113(5):907-15. PMID: 18666209; PMCID: PMC2909006.
    221. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008 Oct 20; 26(30):4875-82. PMID: 18725648.
      View in: PubMed
    222. Rohan TE, Negassa A, Chlebowski R, Lasser NL, McTiernan A, Schenken RS, Ginsberg M, Wassertheil-Smoller S, Page DL. Estrogen plus progestin and risk of benign proliferative breast disease. Cancer Epidemiol Biomarkers Prev. 2008 Sep; 17(9):2337-43. PMID: 18725513; PMCID: PMC2584343.
    223. Chlebowski R. Clinical trial presentations, agency guidelines, and oncology practice: findings from the arimidex, tamoxifen, alone or in combination trial. Clin Breast Cancer. 2008 Aug; 8(4):343-6. PMID: 18757261.
      View in: PubMed
    224. Rohan TE, Negassa A, Caan B, Chlebowski R, Curb JD, Ginsberg M, Lane DS, Neuhouser ML, Shikany JM, Wassertheil-Smoller S, Page DL. Low-fat dietary pattern and risk of benign proliferative breast disease: a randomized, controlled dietary modification trial. Cancer Prev Res (Phila). 2008 Sep; 1(4):275-84. PMID: 19138971; PMCID: PMC3893100.
    225. Col NF, Chlebowski R. Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk. Menopause. 2008 Jul-Aug; 15(4 Suppl):804-9. PMID: 18596602.
      View in: PubMed
    226. Kabat GC, Kim M, Hunt JR, Chlebowski R, Rohan TE. Body mass index and waist circumference in relation to lung cancer risk in the Women's Health Initiative. Am J Epidemiol. 2008 Jul 15; 168(2):158-69. PMID: 18483121; PMCID: PMC2878097.
    227. Prentice RL, Chlebowski R, Stefanick ML, Manson JE, Langer RD, Pettinger M, Hendrix SL, Hubbell FA, Kooperberg C, Kuller LH, Lane DS, McTiernan A, O'Sullivan MJ, Rossouw JE, Anderson GL. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol. 2008 Jun 15; 167(12):1407-15. PMID: 18448442; PMCID: PMC2703736.
    228. Rohan TE, Negassa A, Chlebowski R, Habel L, McTiernan A, Ginsberg M, Wassertheil-Smoller S, Page DL. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst. 2008 Apr 16; 100(8):563-71. PMID: 18398105.
      View in: PubMed
    229. Chlebowski R. Translating trial data into patients benefits: making the right choice. Breast. 2008 Apr; 17 Suppl 3:S9-15. PMID: 18367397.
      View in: PubMed
    230. Miaskowski C, Shockney L, Chlebowski R. Adherence to oral endocrine therapy for breast cancer: a nursing perspective. Clin J Oncol Nurs. 2008 Apr; 12(2):213-21. PMID: 18390458.
      View in: PubMed
    231. Prentice RL, Chlebowski R, Stefanick ML, Manson JE, Pettinger M, Hendrix SL, Hubbell FA, Kooperberg C, Kuller LH, Lane DS, McTiernan A, Jo O'Sullivan M, Rossouw JE, Anderson GL. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol. 2008 May 15; 167(10):1207-16. PMID: 18372396; PMCID: PMC2670848.
    232. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski R, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008 Mar 05; 299(9):1036-45. PMID: 18319414.
      View in: PubMed
    233. Chlebowski R. Pre-empting breast cancer: where do we go from here? Womens Health (Lond). 2008 Mar; 4(2):113-4. PMID: 19072509.
      View in: PubMed
    234. Chlebowski R, Anderson G, Pettinger M, Lane D, Langer RD, Gilligan MA, Gillian MA, Walsh BW, Chen C, McTiernan A. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med. 2008 Feb 25; 168(4):370-7; quiz 345. PMID: 18299491.
      View in: PubMed
    235. Goss PE, Richardson H, Chlebowski R, Johnston D, Sarto GE, Maunsell E, Ingle JN, Alés-Martinez JE. National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women. Clin Breast Cancer. 2007 Dec; 7(11):895-900. PMID: 18269782.
      View in: PubMed
    236. Chlebowski R, Blackburn GL. Diet and breast cancer recurrence. JAMA. 2007 Nov 14; 298(18):2135; author reply 2135-6. PMID: 18000193.
      View in: PubMed
    237. Chlebowski R, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, Sarto G, Rosenberg CA, Hubbell FA. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst. 2007 Nov 21; 99(22):1695-705. PMID: 18000216.
      View in: PubMed
    238. Prentice RL, Thomson CA, Caan B, Hubbell FA, Anderson GL, Beresford SA, Pettinger M, Lane DS, Lessin L, Yasmeen S, Singh B, Khandekar J, Shikany JM, Satterfield S, Chlebowski R. Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst. 2007 Oct 17; 99(20):1534-43. PMID: 17925539; PMCID: PMC2670850.
    239. Cui Y, Page DL, Chlebowski R, Beresford SA, Hendrix SL, Lane DS, Rohan TE. Alcohol and folate consumption and risk of benign proliferative epithelial disorders of the breast. Int J Cancer. 2007 Sep 15; 121(6):1346-51. PMID: 17534897.
      View in: PubMed
    240. Santen RJ, Boyd NF, Chlebowski R, Cummings S, Cuzick J, Dowsett M, Easton D, Forbes JF, Key T, Hankinson SE, Howell A, Ingle J. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer. 2007 Jun; 14(2):169-87. PMID: 17639036.
      View in: PubMed
    241. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski R, Feuer EJ, Edwards BK, Berry DA. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007 Apr 19; 356(16):1670-4. PMID: 17442911.
      View in: PubMed
    242. Chlebowski R, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology. 2006; 71(1-2):1-9. PMID: 17344666.
      View in: PubMed
    243. Cui Y, Page DL, Chlebowski R, Hsia J, Allan Hubbell F, Johnson KC, Rohan TE. Cigarette smoking and risk of benign proliferative epithelial disorders of the breast in the Women's Health Initiative. Cancer Causes Control. 2007 May; 18(4):431-8. PMID: 17323143.
      View in: PubMed
    244. Chlebowski R. Lifestyle change including dietary fat reduction and breast cancer outcome. J Nutr. 2007 01; 137(1 Suppl):233S-235S. PMID: 17182832.
      View in: PubMed
    245. Chlebowski R, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, Hudis C, Butler J, Merkel D, Kristal A, Caan B, Michaelson R, Vinciguerra V, Del Prete S, Winkler M, Hall R, Simon M, Winters BL, Elashoff RM. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst. 2006 Dec 20; 98(24):1767-76. PMID: 17179478.
      View in: PubMed
    246. McTiernan A, Wu L, Chen C, Chlebowski R, Mossavar-Rahmani Y, Modugno F, Perri MG, Stanczyk FZ, Van Horn L, Wang CY. Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity (Silver Spring). 2006 Sep; 14(9):1662-77. PMID: 17030978.
      View in: PubMed
    247. Chlebowski R. Aromatase inhibitors and breast cancer treatment. JAMA. 2006 Aug 09; 296(6):651; author reply 651. PMID: 16896104.
      View in: PubMed
    248. Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin. 2006 Aug; 22(8):1575-85. PMID: 16870082.
      View in: PubMed
    249. Allison M, Garland C, Chlebowski R, Criqui M, Langer R, Wu L, Roy H, McTiernan A, Kuller L. The association between aspirin use and the incidence of colorectal cancer in women. Am J Epidemiol. 2006 Sep 15; 164(6):567-75. PMID: 16847042.
      View in: PubMed
    250. Anderson GL, Chlebowski R, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL, Aggerwal A, David Curb J, Hendrix SL, Allan Hubbell F, Khandekar J, Lane DS, Lasser N, Lopez AM, Potter J, Ritenbaugh C. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas. 2006 Sep 20; 55(2):103-15. PMID: 16815651.
      View in: PubMed
    251. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, Paskett ED, Vitolins MZ, Furberg CD, Chlebowski R. Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst. 2006 May 17; 98(10):700-7. PMID: 16705124.
      View in: PubMed
    252. Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski R. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006 Apr 12; 295(14):1647-57. PMID: 16609086.
      View in: PubMed
    253. Chlebowski R. Letrozole or tamoxifen in early breast cancer. N Engl J Med. 2006 Apr 06; 354(14):1528-30; author reply 1528-30. PMID: 16602149.
      View in: PubMed
    254. Modugno F, Kip KE, Cochrane B, Kuller L, Klug TL, Rohan TE, Chlebowski R, Lasser N, Stefanick ML. Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. Int J Cancer. 2006 Mar 01; 118(5):1292-301. PMID: 16161054.
      View in: PubMed
    255. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O'Sullivan MJ, Margolis KL, Ockene JK, Phillips L, Pottern L, Prentice RL, Robbins J, Rohan TE, Sarto GE, Sharma S, Stefanick ML, Van Horn L, Wallace RB, Whitlock E, Bassford T, Beresford SA, Black HR, Bonds DE, Brzyski RG, Caan B, Chlebowski R, Cochrane B, Garland C, Gass M, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Jackson RD, Johnson KC, Judd H, Kooperberg CL, Kuller LH, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Lewis CE, Limacher MC, Manson JE. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006 Feb 16; 354(7):684-96. PMID: 16481636.
      View in: PubMed
    256. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SA, Black HR, Blanchette P, Bonds DE, Brunner RL, Brzyski RG, Caan B, Cauley JA, Chlebowski R, Cummings SR, Granek I, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Johnson KC, Judd H, Kotchen JM, Kuller LH, Langer RD, Lasser NL, Limacher MC, Ludlam S, Manson JE, Margolis KL, McGowan J, Ockene JK, O'Sullivan MJ, Phillips L, Prentice RL, Sarto GE, Stefanick ML, Van Horn L, Wactawski-Wende J, Whitlock E, Anderson GL, Assaf AR, Barad D. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006 Feb 16; 354(7):669-83. PMID: 16481635.
      View in: PubMed
    257. Prentice RL, Caan B, Chlebowski R, Patterson R, Kuller LH, Ockene JK, Margolis KL, Limacher MC, Manson JE, Parker LM, Paskett E, Phillips L, Robbins J, Rossouw JE, Sarto GE, Shikany JM, Stefanick ML, Thomson CA, Van Horn L, Vitolins MZ, Wactawski-Wende J, Wallace RB, Wassertheil-Smoller S, Whitlock E, Yano K, Adams-Campbell L, Anderson GL, Assaf AR, Beresford SA, Black HR, Brunner RL, Brzyski RG, Ford L, Gass M, Hays J, Heber D, Heiss G, Hendrix SL, Hsia J, Hubbell FA, Jackson RD, Johnson KC, Kotchen JM, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Henderson MM. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006 Feb 08; 295(6):629-42. PMID: 16467232.
      View in: PubMed
    258. Beresford SA, Johnson KC, Ritenbaugh C, Lasser NL, Snetselaar LG, Black HR, Anderson GL, Assaf AR, Bassford T, Bowen D, Brunner RL, Brzyski RG, Caan B, Chlebowski R, Gass M, Harrigan RC, Hays J, Heber D, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Jackson RD, Kotchen JM, Kuller LH, LaCroix AZ, Lane DS, Langer RD, Lewis CE, Manson JE, Margolis KL, Mossavar-Rahmani Y, Ockene JK, Parker LM, Perri MG, Phillips L, Prentice RL, Robbins J, Rossouw JE, Sarto GE, Stefanick ML, Van Horn L, Vitolins MZ, Wactawski-Wende J, Wallace RB, Whitlock E. Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006 Feb 08; 295(6):643-54. PMID: 16467233.
      View in: PubMed
    259. Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, Kuller LH, LaCroix AZ, Langer RD, Lasser NL, Lewis CE, Limacher MC, Margolis KL, Mysiw WJ, Ockene JK, Parker LM, Perri MG, Phillips L, Prentice RL, Robbins J, Rossouw JE, Sarto GE, Schatz IJ, Snetselaar LG, Stevens VJ, Tinker LF, Trevisan M, Vitolins MZ, Anderson GL, Assaf AR, Bassford T, Beresford SA, Black HR, Brunner RL, Brzyski RG, Caan B, Chlebowski R, Gass M, Granek I, Greenland P, Hays J, Heber D, Heiss G, Hendrix SL, Hubbell FA, Johnson KC, Kotchen JM. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006 Feb 08; 295(6):655-66. PMID: 16467234.
      View in: PubMed
    260. Chlebowski R, Anderson GL, Geller M, Col N. Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use. Clin Breast Cancer. 2006 Feb; 6 Suppl 2:S58-64. PMID: 16595028.
      View in: PubMed
    261. McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski R, Pisano ED, Wang CY, Brunner RL, Johnson KC, Manson JE, Lewis CE, Kotchen JM, Hulka BS. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst. 2005 Sep 21; 97(18):1366-76. PMID: 16174858.
      View in: PubMed
    262. Chlebowski R, Khalkhali I. Abnormal mammographic findings with short-interval follow-up recommendation. Clin Breast Cancer. 2005 Aug; 6(3):235-9. PMID: 16137434.
      View in: PubMed
    263. Nguyen KD, Hara B, Chlebowski R. Utility of two cancer organization websites for a multiethnic, public hospital oncology population: comparative cross-sectional survey. J Med Internet Res. 2005 Jul 01; 7(3):e28. PMID: 15998619; PMCID: PMC1550661.
    264. Col NF, Kim JA, Chlebowski R. Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. Breast Cancer Res. 2005; 7(4):R535-40. PMID: 15987460; PMCID: PMC1175064.
    265. Chlebowski R, Anderson GL. Progestins and recurrence in breast cancer survivors. J Natl Cancer Inst. 2005 Apr 06; 97(7):471-2. PMID: 15812065.
      View in: PubMed
    266. Chlebowski R, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, Adams-Campbell LL, Prentice R. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005 Mar 16; 97(6):439-48. PMID: 15770008.
      View in: PubMed
    267. Chlebowski R. Bone health in women with early-stage breast cancer. Clin Breast Cancer. 2005 Feb; 5 Suppl(2):S35-40. PMID: 15807922.
      View in: PubMed
    268. Chlebowski R. Obesity and early-stage breast cancer. J Clin Oncol. 2005 Mar 01; 23(7):1345-7. PMID: 15684314.
      View in: PubMed
    269. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski R, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29. PMID: 15545664.
      View in: PubMed
    270. Chlebowski R, Pettinger M, Stefanick ML, Howard BV, Mossavar-Rahmani Y, McTiernan A. Insulin, physical activity, and caloric intake in postmenopausal women: breast cancer implications. J Clin Oncol. 2004 Nov 15; 22(22):4507-13. PMID: 15542801.
      View in: PubMed
    271. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004 Apr 14; 291(14):1701-12. PMID: 15082697.
      View in: PubMed
    272. Chlebowski R, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, Adams-Campbell LL, White E. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004 Mar 04; 350(10):991-1004. PMID: 14999111.
      View in: PubMed
    273. Chlebowski R, Col N. Menopausal hormone therapy after breast cancer. Lancet. 2004 Feb 07; 363(9407):410-1. PMID: 14962515.
      View in: PubMed
    274. Chlebowski R, Kim JA, Col NF. Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. Semin Oncol. 2003 Dec; 30(6):776-88. PMID: 14663778.
      View in: PubMed
    275. Braithwaite RS, Chlebowski R, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003 Nov; 18(11):937-47. PMID: 14687281; PMCID: PMC1494944.
    276. Geller ML, Chlebowski R. HT and breast cancer risk. Fertil Steril. 2003 Oct; 80 Suppl 4:5-9; quiz 54-5. PMID: 14568281.
      View in: PubMed
    277. Hebert JR, Patterson RE, Gorfine M, Ebbeling CB, St Jeor ST, Chlebowski R. Differences between estimated caloric requirements and self-reported caloric intake in the women's health initiative. Ann Epidemiol. 2003 Oct; 13(9):629-37. PMID: 14732302.
      View in: PubMed
    278. Ritenbaugh C, Patterson RE, Chlebowski R, Caan B, Fels-Tinker L, Howard B, Ockene J. The Women's Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. Ann Epidemiol. 2003 Oct; 13(9 Suppl):S87-97. PMID: 14575941.
      View in: PubMed
    279. Harris RE, Chlebowski R, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res. 2003 Sep 15; 63(18):6096-101. PMID: 14522941.
      View in: PubMed
    280. Hillner BE, Ingle JN, Chlebowski R, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003 Nov 01; 21(21):4042-57. PMID: 12963702.
      View in: PubMed
    281. Chlebowski R. The American Cancer Society guide for nutrition and physical activity for cancer survivors: a call to action for clinical investigators. CA Cancer J Clin. 2003 Sep-Oct; 53(5):266-7. PMID: 14570226.
      View in: PubMed
    282. Yasmeen S, Romano PS, Pettinger M, Chlebowski R, Robbins JA, Lane DS, Hendrix SL. Re: Short-interval follow-up mammography: are we doing the right thing? J Natl Cancer Inst. 2003 Aug 06; 95(15):1175-6. PMID: 12902453.
      View in: PubMed
    283. Jackson M, Berman N, Huber M, Snetselaar L, Granek I, Boe K, Milas C, Spivak J, Chlebowski R. Research staff turnover and participant adherence in the Women's Health Initiative. Control Clin Trials. 2003 Aug; 24(4):422-35. PMID: 12865036.
      View in: PubMed
    284. Chlebowski R, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003 Jun 25; 289(24):3243-53. PMID: 12824205.
      View in: PubMed
    285. Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski R, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul 01; 21(13):2597-9. PMID: 12732612.
      View in: PubMed
    286. Yasmeen S, Romano PS, Pettinger M, Chlebowski R, Robbins JA, Lane DS, Hendrix SL. Frequency and predictive value of a mammographic recommendation for short-interval follow-up. J Natl Cancer Inst. 2003 Mar 19; 95(6):429-36. PMID: 12644536.
      View in: PubMed
    287. Chlebowski R, McTiernan A. Biological significance of interventions that change breast density. J Natl Cancer Inst. 2003 Jan 01; 95(1):4-5. PMID: 12509389.
      View in: PubMed
    288. Morimoto LM, White E, Chen Z, Chlebowski R, Hays J, Kuller L, Lopez AM, Manson J, Margolis KL, Muti PC, Stefanick ML, McTiernan A. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control. 2002 Oct; 13(8):741-51. PMID: 12420953.
      View in: PubMed
    289. Col NF, Goldberg RJ, Orr RK, Erban JK, Fortin JM, Chlebowski R. Survival impact of tamoxifen use for breast cancer risk reduction: projections from a patient-specific Markov model. Med Decis Making. 2002 Sep-Oct; 22(5):386-93. PMID: 12365480.
      View in: PubMed
    290. Winer EP, Hudis C, Burstein HJ, Chlebowski R, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug 01; 20(15):3317-27. PMID: 12149306.
      View in: PubMed
    291. Chlebowski R, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG, Burstein HJ, Eisen A, Lipkus I, Pfister DG. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002 Aug 01; 20(15):3328-43. PMID: 12149307.
      View in: PubMed
    292. Ernst T, Chang L, Cooray D, Salvador C, Jovicich J, Walot I, Boone K, Chlebowski R. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst. 2002 Apr 17; 94(8):592-7. PMID: 11959892.
      View in: PubMed
    293. Vargas HI, Romero L, Chlebowski R. Management of bloody nipple discharge. Curr Treat Options Oncol. 2002 Apr; 3(2):157-61. PMID: 12057078.
      View in: PubMed
    294. Chlebowski R, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol. 2002 Feb 15; 20(4):1128-43. PMID: 11844838.
      View in: PubMed
    295. Chlebowski R. Breast cancer risk reduction: strategies for women at increased risk. Annu Rev Med. 2002; 53:519-40. PMID: 11818488.
      View in: PubMed
    296. Chlebowski R. Reducing the risk of breast cancer. N Engl J Med. 2000 Jul 20; 343(3):191-8. PMID: 10900280.
      View in: PubMed
    297. Chlebowski R. How many protocols are deferred? One IRB's experience. IRB. 1984 Sep-Oct; 6(5):9-10. PMID: 11650665.
      View in: PubMed